These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38676311)

  • 1. B- and T-Lymphocyte Attenuator in Systemic Lupus Erythematosus Disease Pathogenesis.
    Vendel AC; Jaroszewski L; Linnik MD; Godzik A
    Clin Pharmacol Ther; 2024 Jul; 116(1):247-256. PubMed ID: 38676311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High BTLA Expression Likely Contributes to Contraction of the Regulatory T Cell Subset in Lupus Disease.
    Aubergeon L; Sawaf M; Felten R; Gottenberg JE; Dumortier H; Monneaux F
    Front Immunol; 2021; 12():767099. PubMed ID: 34899718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A herpesvirus entry mediator mutein with selective agonist action for the inhibitory receptor B and T lymphocyte attenuator.
    Šedý JR; Balmert MO; Ware BC; Smith W; Nemčovičova I; Norris PS; Miller BR; Aivazian D; Ware CF
    J Biol Chem; 2017 Dec; 292(51):21060-21070. PubMed ID: 29061848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of B and T Lymphocyte Attenuator in Renal Transplant Recipients with Biopsy-Proven Acute Rejection.
    Wang Z; Yang H; Liu X; Zhang J; Han Z; Tao J; Zhao C; Ju X; Tan R; Gu M
    Med Sci Monit; 2018 Jan; 24():387-396. PubMed ID: 29352109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular basis for herpesvirus entry mediator recognition by the human immune inhibitory receptor CD160 and its relationship to the cosignaling molecules BTLA and LIGHT.
    Kojima R; Kajikawa M; Shiroishi M; Kuroki K; Maenaka K
    J Mol Biol; 2011 Nov; 413(4):762-72. PubMed ID: 21959263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Significance of BTLA and HVEM Expression on Circulating CD4
    Song HF; Chen XJ; Tang PJ; Xu P; Huang ZY; Wang XF
    Viral Immunol; 2022 May; 35(4):291-302. PubMed ID: 35196150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory T cell expression of herpesvirus entry mediator suppresses the function of B and T lymphocyte attenuator-positive effector T cells.
    Tao R; Wang L; Murphy KM; Fraser CC; Hancock WW
    J Immunol; 2008 May; 180(10):6649-55. PubMed ID: 18453584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BTLA Expression and Function Are Impaired on SLE B Cells.
    Wiedemann A; Lettau M; Weißenberg SY; Stefanski AL; Schrezenmeier EV; Rincon-Arevalo H; Reiter K; Alexander T; Hiepe F; Lino AC; Dörner T
    Front Immunol; 2021; 12():667991. PubMed ID: 33968071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BTLA interaction with HVEM expressed on CD8(+) T cells promotes survival and memory generation in response to a bacterial infection.
    Steinberg MW; Huang Y; Wang-Zhu Y; Ware CF; Cheroutre H; Kronenberg M
    PLoS One; 2013; 8(10):e77992. PubMed ID: 24205057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Herpes Simplex Virus 1 Latency and the Kinetics of Reactivation Are Regulated by a Complex Network of Interactions between the Herpesvirus Entry Mediator, Its Ligands (gD, BTLA, LIGHT, and CD160), and the Latency-Associated Transcript.
    Wang S; Ljubimov AV; Jin L; Pfeffer K; Kronenberg M; Ghiasi H
    J Virol; 2018 Dec; 92(24):. PubMed ID: 30282707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BTLA inhibition has a dominant role in the
    Battin C; Leitner J; Waidhofer-Söllner P; Grabmeier-Pfistershammer K; Olive D; Steinberger P
    Front Immunol; 2022; 13():956694. PubMed ID: 36081508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of BTLA/HVEM network in development of gastric cancer.
    Azarafza M; Tehrani M; Valadan R; Maleki I; Mohammad Mehdi Ghaffari-Hamedani S; Ghanadan A; Alizadeh-Navaei R; Ajami A
    Hum Immunol; 2022; 83(8-9):637-644. PubMed ID: 35914980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T cell intrinsic heterodimeric complexes between HVEM and BTLA determine receptivity to the surrounding microenvironment.
    Cheung TC; Oborne LM; Steinberg MW; Macauley MG; Fukuyama S; Sanjo H; D'Souza C; Norris PS; Pfeffer K; Murphy KM; Kronenberg M; Spear PG; Ware CF
    J Immunol; 2009 Dec; 183(11):7286-96. PubMed ID: 19915044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct Changes of BTLA and HVEM Expressions in Circulating CD4
    Liu J; Li J; He M; Zhang GL; Zhao Q
    J Immunol Res; 2018; 2018():4561571. PubMed ID: 30116751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of T cell proliferation through the LIGHT-HVEM-BTLA cosignaling pathway.
    Cheung TC
    Recent Pat DNA Gene Seq; 2009; 3(3):177-82. PubMed ID: 19702559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The inhibitory HVEM-BTLA pathway counter regulates lymphotoxin receptor signaling to achieve homeostasis of dendritic cells.
    De Trez C; Schneider K; Potter K; Droin N; Fulton J; Norris PS; Ha SW; Fu YX; Murphy T; Murphy KM; Pfeffer K; Benedict CA; Ware CF
    J Immunol; 2008 Jan; 180(1):238-48. PubMed ID: 18097025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BTLA Expression on Th1, Th2 and Th17 Effector T-Cells of Patients with Systemic Lupus Erythematosus Is Associated with Active Disease.
    Oster C; Wilde B; Specker C; Sun M; Kribben A; Witzke O; Dolff S
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31514450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The expression and anatomical distribution of BTLA and its ligand HVEM in rheumatoid synovium.
    Shang Y; Guo G; Cui Q; Li J; Ruan Z; Chen Y
    Inflammation; 2012 Jun; 35(3):1102-12. PubMed ID: 22179929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disulfide-Linked Peptides for Blocking BTLA/HVEM Binding.
    Spodzieja M; Kuncewicz K; Sieradzan A; Karczyńska A; Iwaszkiewicz J; Cesson V; Węgrzyn K; Zhukov I; Maszota-Zieleniak M; Michielin O; Speiser DE; Zoete V; Derré L; Rodziewicz-Motowidło S
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors.
    Demerlé C; Gorvel L; Mello M; Pastor S; Degos C; Zarubica A; Angelis F; Fiore F; Nunes JA; Malissen B; Greillier L; Guittard G; Luche H; Barlesi F; Olive D
    J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37230538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.